| Description |
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity[1].
|
| Related Catalog |
|
| In Vitro |
Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells[1]. Western Blot Analysis[1] Cell Line: NR6M cells Concentration: 20 µg/mL Incubation Time: 24 h or 48 h Result: Slightly reduced EGFRvIII levels in NR6M cells.
|
| In Vivo |
Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model[1]. Animal Model: Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX)[1] Dosage: 50 mg/kg Administration: i.p.; twice weekly; for 5 weeks Result: Inhibited tumor growth in EGFRwt expressing xenograft model.
|
| References |
[1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498.
|
